- Home
- KOSS vs BOLD Comparison
KOSS vs BOLD Comparison
Compare KOSS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- BOLD
- Stock Information
- Founded
- KOSS 1953
- BOLD 2018
- Country
- KOSS United States
- BOLD United States
- Employees
- KOSS N/A
- BOLD N/A
- Industry
- KOSS Consumer Electronics/Appliances
- BOLD
- Sector
- KOSS Consumer Staples
- BOLD
- Exchange
- KOSS Nasdaq
- BOLD Nasdaq
- Market Cap
- KOSS 63.0M
- BOLD 81.0M
- IPO Year
- KOSS N/A
- BOLD 2024
- Fundamental
- Price
- KOSS $7.34
- BOLD $2.95
- Analyst Decision
- KOSS
- BOLD Strong Buy
- Analyst Count
- KOSS 0
- BOLD 3
- Target Price
- KOSS N/A
- BOLD $23.00
- AVG Volume (30 Days)
- KOSS 183.8K
- BOLD 57.8K
- Earning Date
- KOSS 11-08-2024
- BOLD 11-11-2024
- Dividend Yield
- KOSS N/A
- BOLD N/A
- EPS Growth
- KOSS N/A
- BOLD N/A
- EPS
- KOSS N/A
- BOLD N/A
- Revenue
- KOSS $12,265,069.00
- BOLD N/A
- Revenue This Year
- KOSS N/A
- BOLD N/A
- Revenue Next Year
- KOSS N/A
- BOLD N/A
- P/E Ratio
- KOSS N/A
- BOLD N/A
- Revenue Growth
- KOSS N/A
- BOLD N/A
- 52 Week Low
- KOSS $2.27
- BOLD $2.82
- 52 Week High
- KOSS $18.73
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- KOSS 50.17
- BOLD N/A
- Support Level
- KOSS $7.00
- BOLD N/A
- Resistance Level
- KOSS $7.83
- BOLD N/A
- Average True Range (ATR)
- KOSS 0.44
- BOLD 0.00
- MACD
- KOSS -0.01
- BOLD 0.00
- Stochastic Oscillator
- KOSS 32.26
- BOLD 0.00
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-cancelling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.